Gilead and Merck Experience Mixed Results in Recent Trials
In the latest biotech updates, AstraZeneca introduces a GLP-1 pill, while GSK makes headlines with a significant cancer startup acquisition worth $10.6 billion.
Editorial Staff
1 min read
Updated 10 days ago
Gilead and Merck have recently reported contrasting outcomes from their latest clinical trials, highlighting the unpredictable nature of drug development.
In related news, AstraZeneca has launched a new GLP-1 pill, which could impact the diabetes treatment landscape.
Additionally, GSK has made a substantial move by acquiring a cancer startup for $10.6 billion, signaling its commitment to expanding its oncology portfolio.